| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 6242533 | Respiratory Medicine | 2011 | 13 Pages |
Abstract
Most patients with moderate to very severe COPD exhibit ATS-defined bronchodilator reversibility based on flow and lung volume measures after budesonide/formoterol pMDI or formoterol treatment. Budesonide/formoterol pMDI also has a rapid (within 5Â min) onset of bronchodilation that is maintained over time compared with formoterol alone.
Keywords
Towards a Revolution in COPD HealthFEV1PBOpMDITLClong-acting β2-adrenergic agonistDPIFVCATSICSUpliftAmerican Thoracic SocietyBronchodilationReversibilityBudesonideChronic obstructive pulmonary diseaseCOPDforced expiratory volume in 1 sLung volumeBudTreatmentLABAinspiratory capacityforced vital capacityTotal lung capacityFormoterolPressurized metered-dose inhalerTORCHPlaceboDry powder inhalerInhaled corticosteroid
Related Topics
Health Sciences
Medicine and Dentistry
Pulmonary and Respiratory Medicine
Authors
Bartolome R. Celli, Donald P. Tashkin, Stephen I. Rennard, Jennifer McElhattan, Ubaldo J. Martin,